HHS Peptide Policy: What the October 2026 Filing Says

On 14 October 2026, the US Department of Health and Human Services and the FDA submitted a document titled "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Management and Budget for review.

That is the confirmed fact, and very nearly the only one. The document has not been published. Its text, the substances it covers, who it applies to and when it would take effect are all unknown. OMB review is not approval, and nothing about the legal position of any peptide has changed.

It is already being reported in places as peptides becoming legal. It is not that.

What the filing actually is

The submission appears in the public regulatory review listing maintained by OMB's Office of Information and Regulatory Affairs, under regulatory identifier 0910-ZD94. The listing records it as received on 14 October 2026, classifies it as a notice rather than a rule, records no legal deadline, and shows a status of pending review.

HHS posted public notice of the submission the following day, which is when news coverage began.

OIRA review is a procedural step that federal agencies pass documents through before issuing them. A document sitting at OMB has not been issued, and OMB can clear it, send it back, or clear it in altered form. Because the submission is classified as a notice rather than a rule, it is not a proposed rule and carries no public comment docket of its own.

What it is reported to do, and why that is not the same thing

Reporting based on people familiar with the filing indicates the policy would allow pharmacies to compound certain peptides on a temporary basis, by way of enforcement discretion.

Enforcement discretion means a regulator stating that it does not intend to enforce a particular rule against a particular group, in this case state-licensed compounding pharmacies. It is worth understanding what that does and does not amount to.

It does not change the underlying law. It does not approve any product. The substances concerned would remain unapproved drugs. And because it is not a rule, it can be narrowed or withdrawn without rulemaking or a comment period.

All of that is also still a description of a document nobody outside government has read.

How this fits with the July vote

This follows a sequence worth laying out, because the steps are routinely collapsed into one another.

In February 2026, the HHS Secretary publicly supported broader peptide access.

On 15 April, the FDA removed twelve peptides from Category 2 of its interim bulks policy. That lifted a safety designation. It did not make any peptide eligible for compounding.

On 29 June, FDA staff recommended that none of the seven peptides then under review be added to the 503A Bulks List. The same day, the agency announced a reconstituted Pharmacy Compounding Advisory Committee, around half of whose members had ties to peptide businesses or clinics.

On 23 and 24 July, that committee recommended six of the seven: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. BPC-157, KPV and TB-500 each passed eight votes to six with one abstention. Emideltide was rejected six to seven with one abstention.

As of today, no peptide has been added to the 503A Bulks List. The committee's votes are advisory. Adding a substance requires the FDA to accept the recommendation, publish a proposed rule, take comments and issue a final rule, and that rulemaking has not begun. No statute sets a deadline for it. For scale, the FDA proposed a rule on ten bulk substances in 2016 and did not finalise it until 2019; legal commentators suggest a final rule here could land in late 2027 or 2028.

A further advisory committee meeting is expected before the end of February 2027 to consider GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF. No date has been set.

Some trade bodies have argued that the FDA cannot lawfully authorise compounding through an interim policy while rulemaking is pending. That question is unresolved.

The enforcement that happened while this was going on

This is the part the access coverage has largely omitted, and it is the more immediately consequential development.

On 24 August 2026, the FDA issued five warning letters to online peptide vendors. The agency's finding was that "research use only" labelling did not outweigh the evidence that the products were being bought for human use.

That is a regulator applying, in writing, the reasoning that the label follows the reality of the transaction rather than the other way round. It is the same analysis European and UK regulators have applied, and it is now on the record in the jurisdiction most often cited as the permissive one.

Two further items from the same period. On 18 September the FDA wrote to a compounder about GLP-1 products with added B12 or niacinamide, and questioned prescriptions generated through preselected telehealth options. And across August and September, the FDA and CDC reported more than two dozen illnesses across at least four states linked to compounded glutathione injections.

So the US picture in the second half of 2026 is not deregulation. It is a possible narrow opening for licensed pharmacies, running alongside active enforcement against online supply to consumers.

Why none of this changes anything in Ireland

The 503A framework is a feature of US compounding law. Ireland and the EU have no equivalent mechanism, no compounding bulks list, and no process by which a US enforcement decision confers any status here.

In Ireland, a product meeting the definition of a medicinal product requires a marketing authorisation, assessed by the EMA or the HPRA. That is unaffected by anything at OMB.

Even taken at its most permissive, a US interim policy of this kind would concern state-licensed American pharmacies preparing prescriptions for individual patients. Reporting indicates it would not extend to research-use-only products, dietary supplements, or 503B outsourcing facilities. It would not make any substance an approved medicine, and it would not make anything lawful to sell to a consumer in Ireland.

What to watch

Four things would each represent a real change, and nothing before them does:

• The OMB listing moving from pending to concluded
• Publication of the HHS and FDA document itself
• A Federal Register notice or FDA announcement setting out the policy
• A proposed rule on the 503A Bulks List, with a public docket

Until one of those appears, the position is unchanged regardless of how any announcement is characterised.

About this article

This is a summary of a US regulatory process and its status as of 19 October 2026. It is not legal advice and it is not medical advice, and nothing here is a recommendation to use any substance mentioned.

This is moving week to week. Check the OIRA listing and the FDA's own announcements before relying on anything above.

---

Word count: ~1,180

Sources used (all worth linking):

• OMB/OIRA regulatory review listing, identifier 0910-ZD94
• Holland & Knight alert, 16 October 2026, "Peptides at a Crossroads"
• STAT, 15 October 2026, on the OMB submission
• FDA PCAC July 2026 meeting page and staff briefing document
• FDA warning letters, 24 August 2026

Cannibalisation: this targets "HHS peptide policy" and the October filing. The FDA peptide vote post targets "FDA peptide vote" and the July meeting. Keep them distinct — this post should not re-litigate the July vote beyond the timeline section, and that post should not cover the OMB filing beyond one sentence and a link.

Update needed in the FDA peptide vote post: its "Where things stand now" section says the FDA has not published a proposed rule and has not set a timeline. Still true, but it now predates the OMB submission. Add a sentence noting the 14 October filing and link here.